Schering-Plough has exercised its right to initiate additional discovery and development programs under its collaboration with XOMA, Ltd. for therapeutic antibody products. XOMA received up-front payments for each additional program and will receive research funding for each project as well as success based milestones and royalties on any product sales that result from the collaboration. “We have made significant progress on the first product program since its initiation with Schering...